The CATSINDO Trial - Clinical and Translational Study in Newly Diagnosed Osteosarcoma
The goal of this study is to learn whether children, adolescents, and young adults with newly diagnosed high-grade osteosarcoma can be safely discharged from the hospital at slightly higher methotrexate blood levels after receiving standard high-dose methotrexate chemotherapy. Participants are 22 years old or younger and are receiving standard MAP (high-dose methotrexate with doxorubicin and cisplatin) chemotherapy as part of their routine cancer treatment.
The main questions this study aims to answer are:
- Is hospital discharge at higher methotrexate levels safe, based on side effects or hospital re-admission within 7 days?
- Can patient-derived osteosarcoma tumor organoids be successfully generated across multiple centers?
Researchers will compare safety outcomes and hospital length of stay to historical patient data discharged at lower methotrexate levels.
Participants will receive standard chemotherapy, meet study-defined discharge criteria, be monitored for side effects, and have the option to provide tumor and blood samples for future research.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
This Phase II, multi-institutional study evaluates the safety of hospital discharge at higher serum methotrexate (MTX) levels in children, adolescents, and young adults with newly diagnosed high-grade osteosarcoma receiving standard-of-care high-dose methotrexate (HD-MTX) as part of MAP chemotherapy.
Participants are discharged once they meet the pre-defined MTX clearance, kidney function, and clinical safety criteria. Methotrexate discharge thresholds are evaluated using an adaptive Bayesian threshold-finding design, starting at a serum MTX level of less than or equal to 0.15 micromolar, with possible escalation or de-escalation based on observed toxicity.
Secondary objectives include comparison of hospital length of stay and estimated inpatient costs with historical controls using traditional discharge criteria. Optional correlative studies include patient-derived osteosarcoma tumor organoids and circulating tumor cells to evaluate chemotherapy sensitivity and other future research. A separate retrospective chart review of prior patients treated with HD-MTX is included to understand safety outcomes and MTX clearance patterns.
Type d'étude
Inscription (Estimé)
Phase
- Phase 2
Contacts et emplacements
Coordonnées de l'étude
- Nom: Heather Neagle
- Numéro de téléphone: 980-442-2303
- E-mail: heather.neagle@advocatehealth.org
Lieux d'étude
-
-
North Carolina
-
Chapel Hill, North Carolina, États-Unis, 27599
- University of North Carolina at Chapel Hill
-
Contact:
- Juanita Cuffree, MPH
- Numéro de téléphone: 919-966-0017
- E-mail: cuffree@med.unc.edu
-
Chercheur principal:
- Ian Davis, MD, PhD
-
Charlotte, North Carolina, États-Unis, 28204
- Novant Health Hemby Children's Hospital
-
Chercheur principal:
- Jessica Bell, MD
-
Contact:
- Eliana Sanchez-Ocampo
- Numéro de téléphone: 704-384-1199
- E-mail: Eliana.Sanchez@novanthealth.org
-
Durham, North Carolina, États-Unis, 27710
- Duke University Medical Center
-
Chercheur principal:
- Jessica Sun, MD
-
Contact:
- Morgan Low, MSW
- Numéro de téléphone: 919-613-1895
- E-mail: morgan.low@duke.edu
-
Greenville, North Carolina, États-Unis, 27834
- East Carolina University
-
Contact:
- Tori Donadio, MPH
- Numéro de téléphone: 252-744-2301
- E-mail: donadiov21@ecu.edu
-
Chercheur principal:
- Andrea Whitfield, DO
-
Winston-Salem, North Carolina, États-Unis, 27157
- Atrium Health Wake Forest Baptist
-
Chercheur principal:
- Sarah Supples, MD
-
Contact:
- Nicole Johnson, BS
- Numéro de téléphone: 336-702-4498
- E-mail: nicole.johnson3@advocatehealth.org
-
-
South Carolina
-
Charleston, South Carolina, États-Unis, 29425
- Medical University of South Carolina
-
Chercheur principal:
- Jacqueline Kraveka, DO
-
Contact:
- Monica Martino
- Numéro de téléphone: 843-792-1465
- E-mail: cto-peds-onc@musc.edu
-
Columbia, South Carolina, États-Unis, 29203
- Prisma Health Midlands
-
Contact:
- Carrie Ross, RN, BSN
- Numéro de téléphone: 803-434-7099
- E-mail: Carrie.Ross@PrismaHealth.org
-
Chercheur principal:
- Chandni Dargan, MD
-
Greenville, South Carolina, États-Unis, 29605
- Prisma Health Upstate
-
Chercheur principal:
- Chandni Dargan, MD
-
Contact:
- Tranaka Fuqua, MBA, CCRP, BSN, RN
- Numéro de téléphone: 864-455-5158
- E-mail: Tranaka.Fuqua@prismahealth.org
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Enfant
- Adulte
Accepte les volontaires sains
La description
Pre-Enrollment Criteria:
- Suspected diagnosis of high-grade osteosarcoma based on clinical and radiographic findings.
- Informed consent (and assent, if applicable) obtained, per institutional guidelines.
- Participants must be ≤ 22 years of age at the time of consent.
Inclusion Criteria:
- Participants with localized or metastatic high-grade osteosarcoma.
- Participants must be ≤ 22 years of age at the time of consent.
- Participants must have a body surface area of greater than or equal to 0.8 m2.
Participants receiving or planning to receive induction/neoadjuvant MAP chemotherapy with HD-MTX given at the standard dose of 12 gm/m2 (maximum 20 gm).
NOTE: Participants may be participating on other clinical studies such as the COG trial AOST2032 or any other clinical trial as long as their treatment includes MAP chemotherapy with the standard HD-MTX dose of 12 gm/m2 (maximum 20 gm).
- Participants may receive other chemotherapy agents in their treatment provided that drug(s) are not known to interfere with HD-MTX clearance when given concurrently. Medications known to interfere with HD-MTX clearance are listed in Appendix A.
Participants must meet minimum organ function requirements to receive HD-MTX:
- Adequate liver function defined as: total bilirubin ≤ 1.5x upper limit of normal (ULN) for age at the time of consent and alanine aminotransferase (ALT/SGPT) ≤ 135 U/L for age at the time of consent.
- Adequate renal function defined as: a serum creatinine based on age/gender OR - a 24-hour urine Creatinine clearance ≥ 70 mL/min/1.73 m2, OR - an estimated glomerular filtration rate (GFR) of greater than or equal to 70 mL/min/1.73 m2 for age at the time of consent.
- Adequate bone marrow function defined as: peripheral absolute neutrophil count (ANC) ≥ 1000/µL, platelet count ≥ 100,000/µL (transfusion independent, defined as not receiving platelet transfusions within a 7-day period prior to enrollment), and hemoglobin ≥ 8.0 g/dL (transfusion independent, defined as not receiving red blood cell transfusions within a 7-day period prior to enrollment)
Adequate cardiac function, defined as a left ventricular ejection fraction (LVEF) ≥ 50%, assessed per institutional standard of care using non-invasive imaging modalities such as a Multi-Gated Acquisition (MUGA) scan or echocardiogram (echo).
NOTE: Cardiac function assessment will be performed as part of routine clinical care. No additional imaging or procedures will be mandated by the research protocol.
- Informed consent, and assent when appropriate, must be obtained, per institutional guidelines.
- Participants can enroll after initiation of induction MAP chemotherapy so long as they are enrolled prior to the second cycle of chemotherapy (prior to week 6 cisplatin and doxorubicin).
- Participants must be willing and able to comply with all study procedures for the entire length of the study.
Exclusion Criteria:
Female participants who are pregnant and/or lactating and breast feeding their infant(s).
NOTE: Pregnancy testing will follow institutional standard of care practice and is not mandated by the protocol.
- Sexually active participants of reproductive potential who have not agreed to use an effective contraceptive method for the duration of protocol therapy, at the discretion of the investigator.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Soins de soutien
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Standard-of-Care MAP Chemotherapy with Threshold-Adjusted HD-MTX Discharge
Participants with newly diagnosed high-grade osteosarcoma receive standard-of-care MAP chemotherapy, including high-dose methotrexate (HD-MTX), with hospital discharge based on serum methotrexate threshold levels (ranging from ≤0.10 µM to ≤0.20 µM) and renal function criteria to evaluate the safety of earlier discharge.
Threshold levels are not randomized and are evaluated sequentially over the course of the study.
|
High-dose methotrexate (HD-MTX) is administered intravenously at a dose of 12 g/m² (maximum dose 20 g) over 4 hours as part of standard-of-care MAP chemotherapy for participants with newly diagnosed high-grade osteosarcoma.
HD-MTX is delivered with standard supportive care measures, including alkalinized intravenous hydration, serial serum methotrexate level monitoring, and leucovorin rescue beginning 24 hours after methotrexate initiation and continued until discharge criteria are met.
Treatment is administered according to institutional standards throughout neoadjuvant/induction and adjuvant/consolidation therapy.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Incidence of Dose Limiting Toxicity (DLT)
Délai: Within 7-days post-discharge of methotrexate visit
|
A binary response for dose-limiting toxicity following MTX visit discharge defined as rehospitalization due to acute toxicity or serious adverse event of special interest
|
Within 7-days post-discharge of methotrexate visit
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Length of Stay (LOS)
Délai: From time of admission to time of discharge in hours for each HD-MTX inpatient cycle, assessed across [up to] 12 cycles per participant, through completion of HD-MTX therapy (up to approximately 30 weeks per participant from first week of treatment)
|
Length of hospital stay measured in hours from time of admission to time of discharge for each HD-MTX inpatient cycle
|
From time of admission to time of discharge in hours for each HD-MTX inpatient cycle, assessed across [up to] 12 cycles per participant, through completion of HD-MTX therapy (up to approximately 30 weeks per participant from first week of treatment)
|
|
Patient Cost Per Visit
Délai: Approximately 30 weeks per participant from first week of treatment
|
Total estimated cost associated with each HD-MTX inpatient cycle, based on hospital billing charges and nights of stay
|
Approximately 30 weeks per participant from first week of treatment
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Thomas Russell, MD, Alliance for Research and Innovations in Pediatric Oncology (ARISE) Cancer Consortium
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- Pro00081644 (Advarra IRB)
- ARISE-CATSINDO (Autre identifiant: Alliance for Research and Innovations in Pediatric Oncology (ARISE) Cancer Consortium)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .